M. Lacevic

1.2k total citations
12 papers, 906 citations indexed

About

M. Lacevic is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Lacevic has authored 12 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Lacevic's work include Histone Deacetylase Inhibitors Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). M. Lacevic is often cited by papers focused on Histone Deacetylase Inhibitors Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). M. Lacevic collaborates with scholars based in United States. M. Lacevic's co-authors include Roohi Ismail‐Khan, Pamela N. Münster, Susan Minton, Gary H. Lyman, Jared Adams, Benjamin Djulbegović, Alan Cantor, Nicole M. Kuderer, Charles L. Bennett and Karen K. Fields and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

M. Lacevic

11 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Lacevic United States	8	328	284	217	181	166	12	906
Jonathan Denne United States	15	105 0.3×	73 0.3×	56 0.3×	17 0.1×	91 0.5×	30	1.3k
Alastair Matheson United States	7	73 0.2×	62 0.2×	101 0.5×	97 0.5×	96 0.6×	14	470
Nan Soon Wong Singapore	20	241 0.7×	41 0.1×	686 3.2×	163 0.9×	66 0.4×	39	1.1k
William B. Wong United States	16	115 0.4×	73 0.3×	299 1.4×	47 0.3×	220 1.3×	65	892
O Abe Japan	9	120 0.4×	50 0.2×	336 1.5×	17 0.1×	21 0.1×	45	736
Monica R. McClain United States	19	177 0.5×	116 0.4×	296 1.4×	61 0.3×	62 0.4×	31	1.4k
Francesco Nuzzo Italy	15	229 0.7×	132 0.5×	710 3.3×	9 0.0×	150 0.9×	48	1.2k
Sophie Beale United Kingdom	17	172 0.5×	57 0.2×	125 0.6×	39 0.2×	209 1.3×	42	911
Gisela Schott Germany	9	49 0.1×	158 0.6×	47 0.2×	100 0.6×	93 0.6×	27	399
Gurvaneet Randhawa United States	14	230 0.7×	72 0.3×	41 0.2×	17 0.1×	91 0.5×	28	597

Countries citing papers authored by M. Lacevic

Since Specialization

Citations

This map shows the geographic impact of M. Lacevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lacevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lacevic more than expected).

Fields of papers citing papers by M. Lacevic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lacevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lacevic. The network helps show where M. Lacevic may publish in the future.

Co-authorship network of co-authors of M. Lacevic

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lacevic. A scholar is included among the top collaborators of M. Lacevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lacevic. M. Lacevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Jain, Rohit, Jingsong Zhang, Zeynep Eroglu, et al.. (2019). The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.. Journal of Clinical Oncology. 37(15_suppl). TPS2662–TPS2662. 1 indexed citations

Münster, Pamela N., Amy P. Moore, Roohi Ismail‐Khan, et al.. (2012). Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology. 30(5). 533–538. 163 indexed citations

Münster, Pamela N., Kenneth T. Thurn, Scott Thomas, et al.. (2011). A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British Journal of Cancer. 104(12). 1828–1835. 315 indexed citations

Münster, Pamela N., M. Lacevic, Scott Thomas, et al.. (2009). Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. Journal of Clinical Oncology. 27(15_suppl). 1075–1075. 13 indexed citations

Münster, Pamela N., M. Lacevic, Susan N. Thomas, et al.. (2009). Clinical Phase II Study of Vorinostat, a Hydroxamic Type Histone Deacetylase Inhibitor, in Combination with Tamoxifen To Reverse Acquired Hormone Resistance in Breast Cancer Patients Who Progressed on Hormone Therapy.. Cancer Research. 69(24_Supplement). 6100–6100. 8 indexed citations

Münster, Pamela N., M. Lacevic, Mark R. Schmitt, et al.. (2008). Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. Journal of Clinical Oncology. 26(15_suppl). 3501–3501. 14 indexed citations

Ismail‐Khan, Roohi, S. Minton, Catrin Cox, et al.. (2008). Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 524–524. 28 indexed citations

Münster, Pamela N., Douglas C. Marchion, Morgen Schmitt, et al.. (2007). Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1065–1065. 4 indexed citations

Moulder, Stacy, Nikola Valkov, Jana Gump, et al.. (2006). Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.. Cancer Research. 66. 1270–1271. 1 indexed citations

10.

Moulder, Stacy L., Nikola Valkov, S. Minton, et al.. (2006). A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer: Can localization of topoisomerase I (topo I) predict response to topo I inhibitors?. Journal of Clinical Oncology. 24(18_suppl). 661–661. 2 indexed citations

11.

Djulbegović, Benjamin, Jared Adams, Gary H. Lyman, et al.. (2001). Evaluation and appraisal of randomized controlled trials in myeloma. Annals of Oncology. 12(11). 1611–1617. 11 indexed citations

12.

Djulbegović, Benjamin, M. Lacevic, Alan Cantor, et al.. (2000). The uncertainty principle and industry-sponsored research. The Lancet. 356(9230). 635–638. 346 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact